The mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger domains) is silenced in various human cancers by promoter hypermethylation, suggesting that CHFR is a tumor suppressor. Here, we show that CHFR functions as a negative regulator of the nuclear factor-jB (NF-jB) pathway. Expression of CHFR inhibited NF-jB reporter activity, whereas knockdown of CHFR activated reporter activity. These activities are independent of its RING finger domain. Furthermore, we found that CHFR physically interacts with p65 in cells. Electrophoretic mobility shift assays (EMSAs) and ELISA-based NF-jB-binding assays showed that CHFR negatively regulated transcriptional activity of p65. In addition, our data show that interleukin (IL)-8 is significantly downregulated by CHFR, and that the migration of human endothelial cells is suppressed in culture medium conditioned from CHFR-expressing cancer cells. Using a xenograft model, we show that neovascularization is suppressed by adenovirus-mediated transfer of CHFR. These results indicate that expression of CHFR markedly reduces the expression of IL-8 through the inhibition of NF-jB. As the NF-jB signaling pathway plays a critical role in the development and progression of cancer, our findings show the functional relationship between epigenetic alteration and inflammation/angiogenesis in human cancer cells, thereby showing several potential targets for therapeutic intervention.
Introduction
The CHFR (checkpoint with forkhead and ring finger domains) gene is inactivated by promoter hypermethylation in various types of human malignancies, suggesting that the CHFR protein functions as a tumor suppressor (Privette and Petty, 2008) . Furthermore, earlier studies have shown that Chfr knockout mice were cancer-prone, develop spontaneous tumors and have increased skin tumors after treatment with DMBA. The CHFR protein contains two conserved domains (that is, the forkhead-associated (FHA) domain and the RING finger domain) that have been identified in many different species. Originally, CHFR was believed to mediate a delay in early prophase in response to microtubule stress (Scolnick and Halazonetis, 2000) . The RING finger domain is commonly found in E3 ligase proteins and is thought to influence substrate specificity during ubiquitination reactions (Jackson et al., 2000) . Recent studies have reported that CHFR functions as an E3 ligase in the polyubiqutination of Aurora A and PLK1 (Kang et al., 2002 (Kang et al., , 2004 Yu et al., 2005) , resulting in the degradation of these proteins. In addition, Aurora A accumulation and increased chromosomal instability were observed in MEFs derived from Chfr-deficient mice (Yu et al., 2005) .
As a result of alternative splicing, many types of cancer cells express a CHFR variant that lacks the N-terminal FHA domain (DFHA-CHFR). The DFHA-CHFR variant acts as a trans-dominant inhibitor of fulllength CHFR (Scolnick and Halazonetis, 2000; Toyota et al., 2003) . FHA domains were first identified in forkhead-type transcription factors, but are now known to exist in various proteins (Hofmann and Bucher, 1995) . Many FHA-containing proteins play important roles in the regulation of DNA repair, the cell cycle and apoptosis (Durocher and Jackson, 2002) . More than 200 other FHA-containing proteins have also been identified; however, the functions of many of these proteins remain unknown.
The tumor-suppressing function of CHFR is thought to be mediated by checkpoint regulation as an E3 ligase through the RING finger domain. However, very little work has focused on function of the FHA domain by interactions with multiple transcriptional regulators. Recently, decreased CHFR expression in breast cancer cells was found to result in phenotypes associated with malignant progression, including amplified anchorageindependent colony formation, increased motility and enhanced invasiveness (Privette et al., 2007) . However, the mechanisms underlying the effects of CHFR on the motility and invasiveness of cancer cells are poorly understood. Recently, Fukuda et al. (2008) reported that the anti-proliferative effects of CHFR depend on the FHA domain, rather than on the E3 ligase activity mediated by the RING finger domain (Fukuda et al., 2008) .
We carried out cDNA microarray analysis to determine whether CHFR plays a role in transcriptional regulation. Our results show that CHFR downregulates the pro-inflammatory chemokine, interleukin-8 (IL-8), a target of nuclear factor-kB (NF-kB). In addition, CHFR interacts with RelA (p65) to suppress NF-kB signaling. Using a xenograft model of human cancer, we show that neovascularization is suppressed by adenovirus-mediated transfer of CHFR. Our data identify a novel mechanism by which inactivation of the tumor suppressor, CHFR, results in cancer progression.
Results

CHFR downregulates NF-kB-dependent transcription
To address the effects of CHFR on gene regulation, we carried out a cDNA microarray analysis (using Affymetrix GeneChips, Affymetrix, Santa Clara, CA, USA) of HCT116 cells that had been infected with recombinant adenoviruses expressing either CHFR (Ad-CHFR) or Ad-EGFP ( Figure 1a) . We chose to use HCT116 cells because the CHFR gene is epigenetically silenced in this colorectal cancer cell line . The expression of several NF-kB target genes was substantially downregulated in CHFR-infected cells. To validate the results of our global gene expression analysis, we examined the reduction of representative NF-kB targets using real-time RT-PCR. The real-time RT-PCR analysis showed that expression of several NF-kB target genes, particularly IL8, was considerably lower in HCT116 cells after infection with Ad-CHFR than after infection with Ad-EGFP (Figure 1b) . It is noteworthy that the reduction in expression level varied among the NF-kB target genes. Several different cis-acting elements, together with a binding site for the inducible NF-kB, have been identified within the regulatory regions of NF-kB target genes. The varying effects of CHFR most likely reflect differences in the mechanisms of regulation for each of the NF-kB target genes. To examine the role of CHFR in regulation of the NF-kB signaling pathway, we carried out reporter assays using a luciferase reporter (pNF-kB-Luc). CHFR-expressing cells (HEK293 and HSC3) and cancer cells lacking CHFR expression (HCT116, DLD1, HSC45 and HeLa) were co-transfected with pNF-kBLuc and either a CHFR-expressing plasmid or an empty plasmid. The luciferase activity was lower in the CHFRnegative cells co-transfected with the CHFR expression vector (Figure 1c, left panel) . In contrast, transfection of CHFR had little effect on NF-kB reporter activity in the CHFR-expressing cells (Figure 1c, right panel) .
We next examined whether knockdown of CHFR would trigger NF-kB activity in human cells. Transfection of HEK293 cells with an shRNA expression vector (either CHFR-shRNA1 or CHFR-shRNA2, see Materials and methods) decreased CHFR expression by o40% (Figure 1d , left panel). We then co-transfected HEK293 and HCT116 cells with the NF-kB reporter plasmid, and either with an shRNA expression vector or with an empty vector (pSilencer). Knockdown of CHFR increased NF-kB reporter activity in HEK293 cells (Figure 1d, middle panel) . Introduction of the CHFRshRNAs into HCT116 cells, which lack CHFR expression, did not affect NF-kB reporter activity (Figure 1d , right), indicating that these outcomes were not due to off-target effects. These results suggest that CHFR downregulates basal NF-kB transcriptional activity.
CHFR suppresses NF-kB activity in a RING domainindependent manner The CHFR protein contains FHA and RING domains, which contribute to this protein's checkpoint activity. To identify the specific domains involved in the regulation of NF-kB activity, we transfected HCT116 and HEK293 cells with the NF-kB reporter plasmid and various deletion constructs of CHFR (Figure 2a) . Expression of each CHFR deletion construct was similar (Figure 2b) . Interestingly, the activities of DRING-CHFR and full-CHFR suppressed NF-kB to similar extents in HCT116 cells (Figure 2c, left panel) . However, the other CHFR deletion constructs partially restored the suppressed NF-kB activity. In HEK293 Immunoblot analysis was carried out using anti-Flag and anti-actin antibodies. (c) HCT116 and HEK293 cells were transfected with an NF-kB luciferase reporter construct, along with a Flag-CHFR deletion construct or with an empty vector (À). Luciferase activity was determined using a dual luciferase assay system. Experiments were carried out in triplicate. Means and standard deviations are indicated by bars and brackets, respectively. **Po0.01 relative to mock samples transfected with empty vectors.
Suppression of IL-8 by CHFR through the inhibition of NF-jB L Kashima et al cells that express CHFR, none of the CHFR deletion mutants had significant effects on NF-kB reporter activity ( Figure 2c , right panel). These results indicate that CHFR does not require the RING domain for suppression of NF-kB-dependent transcription.
CHFR suppresses the DNA-binding activity of NF-kB by interacting with p65 in the nucleus We carried out EMSAs to determine whether CHFR inhibits the sequence-specific DNA-binding activity of the NF-kB protein complex. First, we infected HCT116 cells with Ad-CHFR or Ad-EGFP, and then incubated nuclear extracts from these cells with a radiolabeled oligonucleotide probe containing an NF-kB DNAbinding site. Two DNA-protein complexes appeared on the gel, which we designated as NF-kB DNA-binding complex I (upper band) and II (lower band). Complex I was significantly reduced in Ad-CHFR-infected cells ( Figure 3a , lanes 1 and 2 and lower graph). The NF-kB transcription factor is a dimeric complex consisting of Rel/NF-kB family proteins, such as RelA (p65), RelB, c-Rel, NFKB1 (p105/p50) and NFKB2 (p100/p52). Supershift analyses were carried out using specific antibodies against each component of NF-kB to determine which components contribute to the reduction of DNA-protein binding by CHFR. An antibody specific to the p65 subunit shifted the mobility of the complex I and complex II bands ( Figure 3a , lane 3), whereas antibodies against p50 and c-Rel supershifted only complex II ( Figure 3a , lanes 4 and 7). In addition, antibodies against p52 and RelB shifted the mobility of . Nuclear extracts were incubated with a 32 P-labeled oligonucleotide probe (5 0 -AGTTGAGGGGACTTTCCCAGGC-3 0 ) containing an NF-kBbinding site (underlined), and complexes were resolved in a 4% nondenaturing polyacrylamide gel. Supershift analysis (right) was carried out by preincubation with antibodies against various NF-kB/Rel subunits. Arrows indicate DNA-protein complexes I and II (top). Complex I represents p65 homodimers and complex II contains p65/p50 and p65/c-Rel heterodimers. Densitometry and quantification of EMSAs (bottom). (b) Nuclear extracts from HCT116 cells infected with Ad-CHFR or Ad-EGFP were monitored using ELISA-based colorimetric assays. Wild-type consensus NF-kB (WT oligo) and mutated oligonucleotides (mut oligo) were used in competition experiments. Experiments were carried out in triplicate. Means and standard deviations are indicated by bars and brackets, respectively. *Po0.05 relative to mock Ad-EGFP-infected samples. (c) Immunofluorescence analysis of HCT116 cells transfected with Flag-CHFR expression plasmids. Cells were fixed, stained with antibodies to the Flag epitope (red) and to p65 or p50 (green), incubated with the appropriate secondary antibodies and analysed using double immunofluorescence assays. Colocalization of p65 and CHFR in the nuclei (yellow coloration in merged images). Nuclei were detected through DAPI staining (blue). Cells expressing and not expressing Flag-CHFR are indicated by arrows and arrowheads, respectively. Bar ¼ 10 mm. (d) HCT116 cells were transfected with Flag-CHFR and myc-p65, as indicated. Equal amounts of protein extracts were pre-cleaned with protein G-Sepharose (Amersham Biosciences), incubated with 4 mg of anti-Flag (IP: Flag, middle column) or anti-myc antibodies (IP: myc, right column) and with 30 ml of 25% protein G-Sepharose and incubated at 4 1C. The immunoprecipitates were washed five times in the HBST buffer and then boiled in the 1 Â SDS sample buffer. Samples were separated in a 10% SDS-PAGE gel, transferred to an Immobilon-P membrane (Millipore, Billerica, MA, USA), probed with antibodies specific to the myc-(top row) or Flag-(middle row) epitopes and visualized with enhanced chemiluminescence (Amersham Bioscience).
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L Kashima et al these two complexes slightly (Figure 3a , lanes 5 and 6), indicating that complex I is a p65 homodimer and complex II is mainly composed of p65/p50 and p65/-c-Rel heterodimers, which is consistent with earlier reports (Sathe et al., 2004; Wan et al., 2007) . Therefore, CHFR mainly affected the DNA-binding activity of the p65 homodimer ( Figure 3a , lane 2, complex I). We further validated the role of CHFR in suppression of NF-kB activity using the TransAM NFkB Family Transcription Factor Assay kit (Active Motif), which allows the DNA-binding activity of each subunit of NFkB transcription factors to be quantitatively analysed. Lower levels of activated p65 were observed in nuclear extracts from Ad-CHFR-infected HCT116 cells than in Ad-EGFP-infected HCT116 cells (Figure 3b ). RelB and c-Rel activities were not detectable (date not shown).
The DNA-binding activity of p65 was competed by wild-type oligonucleotides, but not by mutant oligonucleotides ( Figure 3b ). These results suggest that the DNA-binding activity of p65 homodimer is suppressed by CHFR expression. We next carried out an NF-kB luciferase assay in the presence of tumor necrosis factor-a (TNF-a) or IL-1b to examine the role of CHFR under the NF-kB-stimulated conditions. The luciferase activity did not increase significantly in response to TNF-a or recombinant IL1b stimulation in HCT116 cells (Supplementary Figure  S1) . Furthermore, EMSAs with nuclear extracts prepared from HCT116 cells showed that NF-kB transcription factors had already obtained sequence-specific DNA-binding activity in the absence of any stimulation ( Figure 3a , lane 1). These results suggest that NF-kB is constitutively activated in HCT116 cells, consistent with the reports that NF-kB is constitutively activated in various other cancer cell lines, including the colon cancer cell lines HCT116, HT29, HCT15, LoVo, and SW480 (Rakitina et al., 2003; Williams et al., 2008) .
To determine whether the CHFR protein colocalizes with the p65 protein in cells, we transfected HCT116 cells with a Flag-CHFR expression vector and carried out immunostaining using antibodies against p65 and Flag. Endogenous p65 appeared to be colocalized with CHFR in the nucleus of CHFR-transfected HCT116 cells, whereas p65 localized in the cytoplasm as well as in the nucleus of CHFR-negative HCT116 cells (Figure 3c , top panels). In contrast, endogenous p50 did not appear to colocalize with CHFR in CHFR-transfected HCT116 cells (Figure 3c , bottom panels). Similar data were obtained in HeLa cells (data not shown). In general, the IkBs retain NF-kB in the cytoplasm by masking the nuclear localization sequence embedded within the REL homology domain (Karin et al., 2002) . p65 is translocated into the nucleus when it is liberated from IkBa after activation. Our results suggest that CHFR cannot physically associate with the cytoplasmic p65 (in the NF-kB/IkB complex), but can associate with the nuclear p65 (liberated from IkBa).
We subsequently carried out a co-immunoprecipitation assay to determine whether CHFR interacts with p65. HCT116 cells were co-transfected with plasmids expressing Flag-tagged CHFR and myc-tagged p65.
Protein extracts were immunoprecipitated with antiFlag or anti-myc antibodies and subjected to immunoblotting analysis. The results showed that Flag-CHFR associates with myc-p65 in HCT116 cells (Figure 3d ). Similar data were obtained from a co-immunoprecipitation assay using myc-CHFR and Flag-p65 constructs (data not shown). Furthermore, an immunocytochemical analysis showed that the CHFR deletion constructs, FHA-CHFR and CR-CHFR, were localized in the cytoplasm (Supplementary Figure S2) , where p65 is retained by IkBa. FHA-CHFR and CR-CHFR did not associate with myc-p65 (data not shown) and did not significantly suppress NF-kB-dependent transcription in HCT116 cells (Figure 2c ). These findings strongly suggest that CHFR can interact with p65 liberated from IkBa in the nucleus, thereby reducing sequencespecific DNA-binding activity and suppressing NF-kBdependent transcription.
NF-kB-dependent transcription of IL-8 is downregulated by CHFR Expression of IL8, a well-known NF-kB target gene (Matsusaka et al., 1993) , was significantly downregulated by CHFR (Figure 1b) . The transcriptional events required for activation of the IL8 promoter have been extensively studied. In particular, the transcription factors AP-1, NF-IL6 and NF-kB play central roles in the modulation of IL-8 expression. We carried out an IL8 promoter-reporter assay to identify regulatory elements within the IL8 gene necessary for its downregulation by CHFR. Single binding sites for the transcription factors, AP-1, NF-IL6 and NF-kB, have been identified earlier in the IL8 promoter (Yasumoto et al., 1992) . We first cloned a 196-base pair (bp) region of the IL8 promoter containing these known transcription factor-binding elements (Figure 4a ) and inserted the 196-bp fragment and a deleted construct upstream of the luciferase reporter gene (Figure 4b) . These constructs were then used in reporter assays. HCT116 cells were transiently co-transfected with a reporter plasmid and a CHFR expression vector. A luciferase reporter containing a consensus p53-binding site (pGL-p53CBS) was used as a control plasmid (Sasaki et al., 2002) . Figure 4b showed that (1) the pGL-IL8-54 reporter construct encompassing nucleotides À54 to þ 44 of the IL8 gene relative to the transcription start site conferred little luciferase activity; (2) pGL-IL8-152 luciferase activity was significantly reduced by co-transfection of the CHFR expression vector; and (3) CHFR expression did not influence the luciferase activity of pGL-p53CBS. Altogether, these data suggest that nucleotides À152 to À55 of the promoter, which contain the NF-kB response site, are important for the CHFR-mediated transcriptional suppression of IL-8.
We then examined IL-8 protein expression in cell culture medium with an ELISA to determine whether the reduction in IL-8 mRNA was accompanied by decreased protein secretion. Significantly less IL-8 protein was secreted from CHFR-infected HCT116 cells (Figure 4c ).
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CHFR inhibits migration of HUVECs through the regulation of IL-8 expression IL-8 induces migration of endothelial cells and is involved in the regulation of pathological angiogenesis, tumor growth and metastasis (Koch et al., 1992; Yuan et al., 2005) . As CHFR suppresses IL-8 expression, we examined whether it also inhibits the motility of endothelial cells. To this end, we carried out a woundhealing assay to assess the effects of CHFR on the motility of HUVECs. Conditioned media from Ad-CHFR-infected HCT116 cells (CHFR-CM) significantly decreased HUVECs motility compared with those from Ad-EGFP-infected cells (EGFP-CM; Figure 5a , top row). We then inhibited IL-8 function using an IL-8-neutralizing antibody, MAB208, to investigate its role in CHFR-mediated inhibition of cell motility. Cellular motility was inhibited by the neutralizing antibodies against IL-8 (Figure 5a, second row) . Conversely, the inhibitory effects of CHFR-CM on HUVECs migration were abrogated by the addition of recombinant IL-8 (Figure 5a , third row). These data suggest that CHFR inhibits HUVECs migration through the downregulation of IL-8.
We then carried out in vitro assays to examine the role of CHFR in angiogenesis. The effects of CHFR on the chemotactic migration of HUVECs were evaluated using the Matrigel migration assay. The number of HUVECs that migrated from the upper to the lower chamber was significantly lower in HUVECs cultured with CHFR-CM than in HUVECs cultured with EGFP-CM (Figure 5b ). When neutralization antibodies against IL-8 were added, the migration of the cells cultured with EGFP-CM was similar to that of the cells cultured with CHFR-CM (Figure 5b ). These results strongly suggest that CHFR inhibits the migration of HUVECs through downregulation of IL-8.
CHFR represses angiogenesis in a xenograft model of human cancer
To further examine the role of CHFR in the regulation of angiogenesis and tumor growth in vivo, we conducted xenograft studies in immunocompromised nude mice. Animals were divided into two experimental groups. The first cohort was subcutaneously injected with HCT116 cells and received intratumoral injections of Ad-CHFR every 1 days. The second cohort was subcutaneously injected with HCT116 cells and received intratumoral injections of Ad-EGFP (as a control). Animals were monitored for subcutaneous tumor formation and tumor growth rates were determined. Ad-CHFR injection slightly inhibited tumor growth and IL8 expression in experimental animals (data not shown). We speculated that the decrease in tumor growth after Ad-CHFR administration reflected an impairment of angiogenesis. To test this hypothesis, we histochemically evaluated tumor-associated blood vessels for the presence of CD31, an endothelial cell surface marker, which should attenuated vascularization in tumors injected with Ad-CHFR (Figure 6a ). These results suggest that CHFR-mediated inhibition of angiogenesis and tumorigenesis requires IL-8 downregulation through the inhibition of NF-kB signaling.
Discussion
We have shown for the first time that CHFR is involved in gene regulation. CHFR suppressed IL-8 transcription by inhibiting NF-kB in human cancer cells, which subsequently decreased angiogenesis in vivo and the migration of human endothelial cells in vitro. These findings show that CHFR functions as a tumor suppressor through the NF-kB signal pathway (Figure 6b ). Mitotic stress activates NF-kB (Rosette and Karin, 1995) , whereas inhibition of NF-kB results in mitotic arrest (Cude et al., 2007) . Thus, CHFR may act as an antephase checkpoint, not only through 
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L Kashima et al ubiquitination but also through the regulation of NF-kB. We do not know the exact molecular basis for the downregulation of NF-kB signaling in cells expressing CHFR. We propose that CHFR cannot physically interact with the p65 subunit in the NF-kB/IkB complex (the inactivated form in the cytoplasm), but can interact with the p65 subunit when it is liberated from IkBa and has translocated to the nucleus. Although nuclear localization of p65 protein is an index of NF-kB activation, an interaction between p65 and CHFR in the nucleus reduces the sequence-specific DNA-binding activity of p65. Consequently, CHFR negatively regulates transcriptional activity of the NF-kB complex. The FHA domain may be important for CHFR to inhibit the transcriptional activity of p65. In general, FHA domains are protein modules that switch signals in diverse biological pathways by monitoring the phosphorylation of threonine residues of target proteins. The FHA domain of CHFR is important for proper subnuclear localization of CHFR to promyelocytic leukemia protein bodies (Daniels et al., 2004) . Promyelocytic leukemia transcriptionally represses NF-kB by interacting with p65 (Wu et al., 2003) . The DFHA-CHFR mutant does not interact with promyelocytic leukemia, suggesting that CHFR recruitment to promyelocytic leukemia bodies requires the FHA domain and that this recruitment may be relevant to the downregulation of NF-kB. As a next step, we will attempt to clarify the molecular mechanism by which CHFR interacts with and inhibits the transcriptional activity of p65.
As recently discussed, the NF-kB signaling pathway plays a critical role in cancer development and progression. Aberrant activation of NF-kB (arising from mutation, amplification or deletion of NF-kB family members and upstream genes, or aberrant activation of upstream signaling pathways) is frequently observed in many types of human cancers. The first gene in the NF-kB family that was found to be mutated in human After 32 h of incubation, the growth medium was changed to remove adenoviruses and cells were incubated for an additional 16 h. Conditioned media (CM) were collected and used in wound-healing assays. EGFP-CM and CHFR-CM refer to the conditioned media from Ad-CHFR-and Ad-EGFPinfected cells, respectively. HUVECs were grown to confluence on six-well plates and wound-healing assays were carried out using 100 ml of conditioned media in the presence or absence (À) of an anti-IL-8 antibody (400 ng/ml) or in recombinant human IL-8 (0.1 ng/ml). (b) Conditioned media (CM) were placed in the lower chamber in the presence or absence of an anti-IL-8 antibody (400 ng/ml). Subsequently, HUVECs were seeded onto a Matrigel-coated chamber and migration assays were carried out. EGFP-CM and CHFR-CM refer to the conditioned media from Ad-CHFR-and Ad-EGFP-infected cells, respectively. Original magnification, Â 200 (left). The average number of migrating cells was determined by counting the cells under a microscope in at least five different viewing fields. The migration index was normalized to the average number of cells migrating through a control membrane (right).
Suppression of IL-8 by CHFR through the inhibition of NF-jB L Kashima et al lymphoid malignancies was NFKB2 (p100). Subsequent studies showed that chromosomal rearrangements at the NFKB2 locus occur in a variety of human lymphomas (Rayet and Gelinas, 1999) . Other changes to NF-kB family proteins in cancer tissues include the amplification and mutation of REL (c-Rel) in leukemia and lymphomas (Rayet and Gelinas, 1999; Starczynowski et al., 2007) ; mutations in the IKBA (IkBa) gene and hemizygous frameshift mutations in IKBE (IkBe) in Hodgkin's lymphoma (Cabannes et al., 1999; Scolnick and Halazonetis, 2000) (Emmerich et al., 2003) ; the amplification and overexpression of the IKBKE (IKKe) gene, a member of the IKK family, in breast cancer cell lines and patient-derived tumors (Boehm et al., 2007) ; and the mutation or amplification of TRAF2, TRAF3, CYLD, CIAP2, CD40, LTBR, TACI, NIK, CARD11 and other activators of the NF-kB signaling pathway in several cancer types (Campbell et al., 1998; Keats et al., 2007; Lenz et al., 2008) . In our study, several NF-kB target genes (IL8, ZFP36, CXCL1 and IL12A) were downregulated in response to CHFR overexpression (Figure 1b) . The IL6 gene has binding sites for NF-IL6 and NF-kB (Akira et al., 1990; Libermann and Baltimore, 1990) and also plays an important role in tumor development (Mumm and Oft, 2008 ), but we were unable to detect an effect of CHFR on IL6 expression in HCT116 cells in our cDNA microarray analysis. The RT-PCR analysis confirmed that IL6 was not expressed or induced by TNF-a stimulation in HCT116 cells (Supplementary Figure  S3a) . As a control, we used HeLa cells, in which the expression and induction of IL6 were reported earlier (Kontermann et al., 2008) . Therefore, we concluded that IL6 was probably silenced epigenetically or by other means in HCT116 cells. Subsequent RT-PCR experiments showed that the IL-6 expression was downregulated in response to CHFR expression both with and without TNF-a stimulation in HeLa cells (Supplementary Figure S3b ). These results indicate that IL6 is also downregulated by CHFR through inhibition of NF-kB. In contrast, a subset of NF-kB target genes (VEGF, BIRC5, BCL10 and CXCL5, 6) did not respond in the same manner (data not shown). It is possible that CHFR binds other transcription factors that are critical for transactivating a subset of the NF-kB target genes.
Clinical studies have shown that IL-8 is upregulated in several human malignances, including melanoma (Nurnberg et al., 1999) , colon (Cuenca et al., 1992) , stomach (Lee et al., 2004) , non-small-cell lung (Smith et al., 1994) and other types of cancers. Generally, IL-8 production is linked to tumor vascularization, a metastatic phenotype and an overall poor prognosis. The tumor microenvironment and the biological activity of IL-8 in tumors may contribute to tumor progression through the regulation of angiogenesis, cancer cell growth and survival, tumor cell motion, leukocyte infiltration and the immune response.
Expression of IL-8 can be induced by various stimuli, including pro-inflammatory cytokines, bacterial products and various cellular stresses. Kunsch and Rosen (1993) reported that, unlike most other well-characterized (a) Studies were conducted in immunocompromised nude mice by resuspending 3 Â 10 6 of HCT116 cells in 100 ml of sterile PBS and subcutaneously injecting these cells into the flanks of animals using a 21-gauge needle. A total of 3 Â 10 8 plaque forming units (pfu) per 100 ml of adenovirus Ad-CHFR or Ad-EGFP were intratumoraly injected on days 6, 8, 10, 12, 14, 16 and 18 after tumor cell inoculation, using a 26-gauge needle. Mice were killed on day 20 after tumor cell inoculation. For immunohistochemical staining, snap-frozen sections of tumor specimens (10 mm thick) were fixed in acetone. The sections were incubated with an anti-CD31 antibody (1:20) overnight at room temperature, following which the appropriate biotinylated secondary antibody was added. After incubation with the secondary antibody, streptavidin-HRP (horseradish peroxide) was applied (BD Pharmingen) and the subsequent antibody/enzyme conjugate was developed using DAB. All sections were counterstained using hematoxylin. Tumor sections were imaged at low magnification ( Â 4), and blood vessels density was quantified by counting the total number of CD31-positive vessels in each of two fields. For this analysis, eight tumor samples were evaluated for each experimental condition. Suppression of IL-8 by CHFR through the inhibition of NF-jB L Kashima et al NF-kB-binding elements, the NF-kB site within IL8 prefers to bind p65, p52 and c-Rel homodimers rather than to p65-p50 heterodimers and p50 homodimers (Kunsch and Rosen, 1993) . Consistent with these data, we found that the NF-kB site within the IL8 promoter is critical for transcriptional suppression by CHFR, which primarily interacts with p65 homodimers. In this study, we have explored the functional significance of IL-8 downregulation by the tumor suppressor CHFR. Downregulation of IL-8 is necessary for CHFR-induced inhibition of human endothelial cell migration. In addition, tumor vasculature was substantially decreased in CHFR-infected tumors, as determined in a xenograft model. Taken together, our results show that frequent inactivation of CHFR may trigger NF-kB activation in human cancer cells. These observations show the functional relationship between epigenetic alteration and inflammation/angiogenesis in human cancers, and also show several potential targets for therapeutic intervention.
Materials and methods
Cell cultures
Human colorectal cancer cells (HCT116 and DLD1), human stomach cancer cells (HSC45), human oral squamous cell carcinoma cells (HSC3), human cervical carcinoma cells (HeLa), human embryonic kidney cells (HEK293) and monkey kidney cells (COS7) used in this study were purchased from the American Type Culture Collection (Manassas, VA, USA) or the Japanese Collection of Research Bioresources (Tokyo, Japan). Human umbilical vein endothelial cells (HUVECs) were purchased from Cambrex Bio Science (Walkersville, MD, USA). All cells were cultured in appropriate media as recommended by the suppliers.
Plasmids and recombinant adenoviruses
The cDNAs encoding full-length CHFR and deletion constructs (see Figure 2a) were inserted into Flag-tagged pCMVtag2B or pCMV-tag2C vector (Stratagene, La Jolla, CA, USA). The shRNA expression vectors designed to interfere with CHFR expression (CHFR-shRNA1 (pSilencer-CHFR487) and CHFR-shRNA2 (pSilencer-CHFR500)) were described earlier (Ogi et al., 2005) . The pcDNA3-Flag-p65 construct was kindly provided by Dr. Toshiharu Suzuki of Hokkaido University, Japan (Tomita et al., 2000) . Direct sequencing was carried out to verify the integrity of the inserted DNA sequences. Procedures used to generate, purify and infect replication-deficient CHFR-containing recombinant adenoviruses (Ad-CHFR) have been described earlier (Sasaki et al., 2001; Satoh et al., 2003) . A recombinant adenovirus containing the enhanced green fluorescent proteins (EGFP) gene (Ad-EGFP) was generated as a control.
Antibodies
The anti-Flag monoclonal antibody (M2) was obtained from Sigma (St Louis, MO, USA). The anti-myc monoclonal antibody (9E10); anti-CHFR (sc-13288), anti-p65 (sc-109 and sc-372), anti-p50 (sc-1190), anti-p52 (sc-7386), anti-c-Rel (sc-71) polyclonal antibodies; and horseradish peroxide-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-p50 (#3035), anti-p52 (#4882) and anti-RelB (#4954) antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). Alexa 594-and Alexa 488-conjugated secondary antibodies were obtained from Molecular Probes (Carlsbad, CA, USA). The anti-human CXCL8/IL-8 monoclonal antibody (MAB208) was obtained from R&D Systems (Minneapolis, MN, USA). The anti-mouse CD31 monoclonal antibody (MEC13.3) and the biotin-conjugated goat anti-rat, Ig-specific polyclonal antibody were obtained from BD Pharmingen (Franklin Lakes, NJ, USA).
Real-time RT-PCR
Reverse transcription-PCR (RT-PCR) was carried out as described earlier using the TaqMan Gene Expression Assays (Applide Biosystems, Foster City, CA, USA) (Nishikawa et al., 2007) . Relative levels of gene expression were quantified using the DDC t method, which calculated the ratio of target gene expression to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a housekeeping gene. Primer/ probe sets are shown in Supplementary Table S1 .
ELISA assays HCT116 cells were infected with adenovirus Ad-CHFR or Ad-EGFP and cultured in McCoy's 5A medium containing 5% fetal bovine serum. After 32 h, the medium was aspirated and replaced with fresh McCoy's 5A medium containing 5% fetal bovine serum. The cells were then incubated for 16 h, and the conditioned media from Ad-CHFR (CHFR-CM)-or Ad-EGFP (EGFP-CM)-infected cells were collected and centrifuged to remove debris. Conditioned media were analysed in triplicate using a human IL-8-specific ELISA kit (R&D Systems).
Luciferase reporter assays
Cells were plated at a density of 2 Â 10 5 cells per well in 24-well plates. After 24 h, cells were co-transfected with 900 ng of a mammalian expression plasmid or an empty plasmid, in addition to 100 ng of reporter plasmid, pNF-kB-Luc (Stratagene) or human IL-8 promoter-reporter and 2 ng of pRL-TK control reporter vector (Promega, Madison, WI, USA) using LipofectAMINE2000 (Invitrogen, Carlsbad, CA, USA). The pNF-kB-Luc plasmid contains a firefly luciferase reporter gene that was derived from a basic promoter element joined to five tandem repeats of an NF-kB consensus-binding element. Two fragments containing portions of the 5 0 -regions flanking the IL-8 gene were subcloned upstream of the luciferase reporter gene in the pGL3-Basic vector (Promega). These constructs were named pGL-IL8-54 and pGL-IL8-152 (Figure 4a ). Luciferase activities of the reporter plasmids were measured using the Dual-Luciferase Reporter Assay System (Promega), with Renilla luciferase activity used as an internal control.
Electrophoretic mobility shift assays HCT116 cells were infected with Ad-CHFR or Ad-EGFP and cultured in McCoy's 5A medium containing 5% fetal bovine serum for 48 h. Cytoplasmic and nuclear extracts were prepared from the cells using low-and high-salt buffers, respectively, and electrophoretic mobility shift assays (EMSAs) were carried out as described earlier (Kawai et al., 2005) . The oligonucleotide probe was end-labeled using [g-32 P] ATP (Amersham Biosciences, Piscataway, NJ, USA) and T4 polynucleotide kinase (Roche, Basel, Schweiz).
